Research Article 
Do type 2 diabetes patients without diabetic retinopathy or subjects with impaired fasting glucose have impaired colour vision? The Okubo Color Study Report
T. Shoji, Y. Sakurai, H. Sato, E. Chihara and M. Takeuchi
Diabetic Medicine, 2011, 28(7), 865-871. DOI: 10.1111/j.1464-5491.2011.03290.x
Abstract
Aims To investigate associations between fasting plasma glucose level and the prevalence of acquired colour vision impairment in type 2 diabetes patients without diabetic retinopathy.
Methods Participants in this cross-sectional study of male officials aged 20-60 yr in the Japanese Self Defence Force, underwent colour vision testing, ophthalmic examination, a standardized interview and examination of venous blood samples. Ishihara plates, a Lanthony 15-hue desaturated panel and Standard Pseudoisochromatic Plates Part 2 were used to examine colour vision. The Farnsworth-Munsell 100-hue test was performed to define acquired colour vision impairment. Cardiovascular disease risk factors were determined from serum blood samples, physical records and an interview. We performed logistic regression analysis adjusted for age, diagnosed hypertension, dyslipidaemia, cataract, glaucoma, being overweight, smoking status and alcohol intake. Crude and adjusted odds ratios were calculated for three glucose levels, which included normal fasting glucose, impaired fasting glucose and diabetes.
Results Out of a total of 1042 men enrolled, 872 were eligible for the study, and 31 were diagnosed with acquired colour vision impairment. As compared with the subjects with normal fasting glucose (< 5.6 mmol/l), the crude odds ratio for acquired colour vision impairment was 0.93 (95% CI 0.32-2.74) for the subjects with impaired fasting glucose (5.6-6.9 mmol/l) and 8.07 (95% CI 2.48-26.22) for the patients with type 2 diabetes. The multiple-adjusted odds ratios were 0.77 (95% CI 0.25-2.34) for the subjects with impaired fasting glucose and 5.89 (95% CI 1.55-22.40) for the patients with type 2 diabetes.
Conclusions Our findings suggest that there is a dramatically increased prevalence of acquired colour vision impairment in type 2 diabetes patients without diabetic retinopathy which might be attributable to another pathogenesis associated with diabetic retinopathy.
ASCI-ID: 109-877
Similar Articles
Small-fibre involvement in diabetic patients with neuropathic foot pain
Diabetic Medicine, 2008, 25(6), 692-699. DOI: 10.1111/j.1464-5491.2008.02446.x
Nerve growth factor and expression of its receptors in patients with diabetic neuropathyDiabetic Medicine, 2009, 26(12), 1228-1234. DOI: 10.1111/j.1464-5491.2009.02856.x
Cutaneous anaesthesia of the lower leg can improve sensibility in the diabetic foot. A double-blind, randomized clinical trialDiabetic Medicine, 2010, 27(7), 823-829. DOI: 10.1111/j.1464-5491.2010.03014.x
Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysisDiabetic Medicine, 2010, 27(11), 1271-1279. DOI: 10.1111/j.1464-5491.2010.03110.x
Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbiditiesDiabetic Medicine, 2009, 26(1), 61-69. DOI: 10.1111/j.1464-5491.2008.02616.x
Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathyDiabetic Medicine, 2009, 26(3), 240-246. DOI: 10.1111/j.1464-5491.2009.02667.x
Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathyDiabetic Medicine, 2011, 28(10), 1261-1267. DOI: 10.1111/j.1464-5491.2011.03372.x
Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathyDiabetic Medicine, 2011, 28(10), 1253-1260. DOI: 10.1111/j.1464-5491.2011.03299.x
Neuropad: evaluation of three cut-off points of sudomotor dysfunction for early detection of polyneuropathy in recently diagnosed diabetesDiabetic Medicine, 2011, 28(11), 1412-1415. DOI: 10.1111/j.1464-5491.2011.03345.x
Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathyDiabetic Medicine, 2012, 29(6), 771-775. DOI: 10.1111/j.1464-5491.2011.03442.x
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathyDiabetic Medicine, 2012, 29(12), 1529-1533. DOI: 10.1111/j.1464-5491.2012.03684.x
Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population—the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4Diabetic Medicine, 2008, 25(5), 536-542. DOI: 10.1111/j.1464-5491.2008.02423.x
Health utility values associated with diabetic retinopathyDiabetic Medicine, 2008, 25(5), 618-624. DOI: 10.1111/j.1464-5491.2008.02430.x
The Y402H variant of complement factor H is associated with age-related macular degeneration but not with diabetic retinal disease in the Go-DARTS studyDiabetic Medicine, 2009, 26(5), 460-465. DOI: 10.1111/j.1464-5491.2009.02719.x
Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age populationDiabetic Medicine, 2009, 26(5), 489-492. DOI: 10.1111/j.1464-5491.2009.02718.x
Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programmeDiabetic Medicine, 2009, 26(10), 1040-1047. DOI: 10.1111/j.1464-5491.2009.02820.x
Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetesDiabetic Medicine, 2010, 27(4), 431-435.
Is risk of diabetic retinopathy lower in Australia’s Greek-born migrants?Diabetic Medicine, 2010, 27(6), 660-665. DOI: 10.1111/j.1464-5491.2010.03005.x
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT ProgrammeDiabetic Medicine, 2011, 28(3), 345-351. DOI: 10.1111/j.1464-5491.2010.03210.x
Increased levels of monokine induced by interferon-γ (Mig) in the vitreous of patients with diabetic retinopathyDiabetic Medicine, 2008, 25(7), 875-877. DOI: 10.1111/j.1464-5491.2008.02466.x
Reliability of screening methods for diabetic retinopathyDiabetic Medicine, 2009, 26(8), 783-790. DOI: 10.1111/j.1464-5491.2009.02778.x
Blood pressure control and awareness among patients with diabetes and hypertension attending a tertiary ophthalmic clinicDiabetic Medicine, 2009, 26(1), 34-39. DOI: 10.1111/j.1464-5491.2008.02614.x
Diabetic retinopathy screening: a systematic review of the economic evidenceDiabetic Medicine, 2010, 27(3), 249-256. DOI: 10.1111/j.1464-5491.2009.02870.x
Socio-economic and ethnic inequalities in diabetes retinal screeningDiabetic Medicine, 2010, 27(3), 282-288. DOI: 10.1111/j.1464-5491.2010.02946.x
Association between alcohol consumption and diabetic retinopathy and visual acuity-the AdRem StudyDiabetic Medicine, 2010, 27(10), 1130-1137. DOI: 10.1111/j.1464-5491.2010.03080.x
Agreement and reasons for disagreement between photographic and hospital biomicroscopy grading of diabetic retinopathyDiabetic Medicine, 2011, 28(6), 741-746. DOI: 10.1111/j.1464-5491.2011.03273.x
External quality assurance for image grading in the Scottish Diabetic Retinopathy Screening ProgrammeDiabetic Medicine, 2012, 29(6), 776-783. DOI: 10.1111/j.1464-5491.2011.03504.x
Preferences of people with diabetes for diabetic retinopathy screening: a discrete choice experimentDiabetic Medicine, 2012, 29(7), 869-877. DOI: 10.1111/j.1464-5491.2012.03636.x
Diabetic retinopathy screening: perspectives of people with diabetes, screening intervals and costs of attending screeningDiabetic Medicine, 2012, 29(7), 878-885. DOI: 10.1111/j.1464-5491.2012.03637.x
Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countriesDiabetic Medicine, 2013, 30(4), 387-398. DOI: 10.1111/dme.12119